Metformin in Heart Failure Without Diabetes (Met-HeFT)
Columbia University Medical Center is conducting a pilot clinical research study that will assess the use of the medication metformin for heart failure in patients who are not diabetic and have no evidence of insulin resistance.
Patients will received either the study drug metformin or placebo for 4 months. During the study, the patients will undergo extensive testing that will include symptom assesment, exercise capacity, echocardiography, cardiac PET imaging and blood tests.
調査の概要
研究の種類
入学 (予想される)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Barry Fine, MD
- 電話番号:212-305-5755
- メール:bmf2002@cumc.columbia.edu
研究場所
-
-
New York
-
New York、New York、アメリカ、10032
- 募集
- New York Hospital - Columbia University Irving Medical Center
-
コンタクト:
- Andrea Kim
- 電話番号:212-305-1368
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients with chronic heart failure (defined as >6 months duration) uptitrated to recommended or maximally tolerated dose of ACE-I/ARB (unless contraindicated) and beta-blocker (unless contraindicated). If indicated, an aldosterone receptor antagonist should be given (unless contraindicated). An ICD and/or CRT-D should be implanted, if indicated. Patients with a CRT device should be treated for > 3 months.
- Reduced ejection fraction defined as LVEF < 40%
- NYHA-class II or III with stable symptoms for at least the past 3 months
- Renal Function by eGFR > 45 ml/min (MDRD equation) in accordance with FDA guidance on metformin use in CKD
- Ability to understand the written patient information and to give informed consent
- Negative urine-HCG for women of childbearing potential
Exclusion Criteria:
Patients with diabetes or insulin resistant, defined as 1 or more of the following criteria:
- HbA1c >6.0% within the last 12 months prior to enrollment
- Impaired fasting insulin resistance index (HOMA-IR) >2.7
- Any oral or injectable hypoglycemic therapy (e.g. insulin, sulfonylureas)
- Recent Hospitalizations in the past 3 months
- Metformin treatment within the last 3 months
- eGFR below 45 in the prior 6 months
- Known allergy to metformin or major side effects to metformin treatment
- Acute myocardial infarction, unstable angina or revascularization < 3 months at the time of randomization
- Planned coronary revascularization, heart surgery, CRT implantation or other intervention during the study period that would potentially affect the function of the heart
- Significant, uncorrected cardiac valve disease
- Cardiac arrest or life threatening ventricular arrhythmias within the last 3 months (unless treated with an ICD)
- Atrial fibrillation with poorly controlled ventricular rate at rest (> 100 beats/min)
- Hypertrophic or restrictive cardiomyopathy, infiltrative or storage myocardial disease, active myocarditis, or pericardial disease.
- Planned major surgery
- Female patients who are pregnant, nursing, or of childbearing potential while not practicing effective chemical contraceptive methods (i.e. oral, implanted, injectable, or transdermal contraceptive hormones; intrauterine device)
- Current abuse of alcohol or drugs
- Life-expectancy of less than 1 year due to co-existing morbid illness
- Stroke within the last 6 months
- Liver disease with P-ALAT >3 times upper normal limit (it is possible to repeat this measurement once within a month)
- Significant comorbidity or issue that makes the patient unsuitable for participation as judged by the investigator
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Metformin
Metformin for 6 months
|
Metformin starting at 500mg twice a day and increasing to 1000mg twice a day for a total of 6 months
|
プラセボコンパレーター:Placebo
Matched placebo for 6 months
|
Similar dosing regime as active comparator
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
Change in Minute Ventilation to Carbon Dioxide Production (VE/VCO2) Slope
時間枠:Baseline and 6 months
|
Baseline and 6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Change in Dyspnea Assesment Score
時間枠:Baseline and 6 months
|
100mm Visual Analog Scale.
100mm line scale ranging from 0 (worse imaginable breathing) to 100 (best imaginable breathing)
|
Baseline and 6 months
|
Minnesota Health Living with Heart Failure Questionnaire
時間枠:Baseline and 6 months
|
Score
|
Baseline and 6 months
|
Left Ventricular Function Evaluated by Ejection Fraction and Diastolic Function on Echocardiography
時間枠:Baseline and 6 months
|
Baseline and 6 months
|
|
Global Longitudinal Strain and Strain Rate Measured on Echocardiography
時間枠:Baseline and 6 months
|
Baseline and 6 months
|
|
B Type Natriuretic Peptide (BNP) level
時間枠:Baseline and 6 months
|
Baseline and 6 months
|
|
Body Weight
時間枠:Baseline and 6 months
|
kg
|
Baseline and 6 months
|
Peak Myocardial Oxygen Consumption (VO2)
時間枠:Baseline and 6 months
|
Baseline and 6 months
|
|
Quantitative 18F-FDG Activity in 9 Myocardial Segments
時間枠:Baseline and 6 months
|
Glucose Metabolism
|
Baseline and 6 months
|
Quantitative N13-NH3 Activity in 9 Myocardial Segments
時間枠:Baseline and 6 months
|
Perfusion
|
Baseline and 6 months
|
Heart Failure Hospitalizations
時間枠:Over 6 months
|
number
|
Over 6 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Hemoglobin A1c
時間枠:Baseline and 6 months
|
Baseline and 6 months
|
|
Serum Lactate
時間枠:1 month and 6 months
|
1 month and 6 months
|
|
Fasting Sugar
時間枠:1 month and 6 months
|
mg/dl
|
1 month and 6 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Barry Fine, MD、Columbia University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
心不全の臨床試験
-
Novartis Pharmaceuticals完了EC-MPS による治療に関心があり、コア研究の 12 か月の治療期間を無事に完了した患者 (de novo Heart Recipients)
Metformin hydrochlorideの臨床試験
-
Tan Tock Seng Hospital募集
-
Cairo Universityわからない